Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | YAP1 | P46937 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973755 | 1.00 | KIFC1 (0.59) | KIFC1PPARGGAARAB9AGPR34 | |
| SCHEMBL3974468 | 0.90 | KIFC1 (0.70) | KIFC1PPARGGPR34CAPN1FFAR1 | |
| SCHEMBL5927404 | 0.87 | ABCG2 (0.59) | KIFC1PPARGGAARAB9AGPR34 | |
| SCHEMBL1122834 | 0.86 | GAA (0.75) | PPARGGAARAB9AGPR34LTA4H | |
| SCHEMBL6030161 | 0.84 | GAA (0.77) | PPARGGAARAB9AGPR34LTA4H | |
| SCHEMBL4827793 | 0.82 | ABCG2 (0.62) | KIFC1ABCG2HDAC1HDAC6 | |
| SCHEMBL4827796 | 0.82 | ABCG2 (0.62) | KIFC1ABCG2HDAC1HDAC6 | |
| SCHEMBL5926212 | 0.82 | ABCG2 (0.62) | KIFC1ABCG2CDK2HDAC1HDAC6 | |
| SCHEMBL1123055 | 0.82 | GAA (0.80) | PPARGGAARAB9ALTA4HERAP2 | |
| SCHEMBL6662616 | 0.82 | PPARG (0.60) | PPARGGAARAB9AGPR34LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | KIFC1 4686/4885PPARG 148/4885GAA 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.